Categories Annual ReportsCorporate GovernanceDefault CalendarFeatured DocumentsPresentationsProxy Statements Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Title Supernus Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering Code of Ethics Audit Committee Procedures for Handling Complaints Compensation Committee Charter Policy Regarding Shareholder Communications with Directors Governance and Nominating Committee Charter Regulation FD Disclosure Policy Supernus Pharmaceuticals Raises $42 Million to Prepare for Launch of Product Candidates in Epilepsy and Develop Pipeline in ADHD Supernus Pharmaceuticals Initiates Phase IIb Clinical Trial for SPN-810 in Impulsive Aggression Supernus Pharmaceuticals Announces Positive Results from Phase IIa Clinical Trial for SPN-812 in Adults with ADHD Pagination First page « first Previous page ‹ previous … Page 15 Page 16 Page 17 Page 18 Page 19 Page 20 Current page 21 Page 22 Page 23 Next page next › Last page last »